A5037261291- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Neonatal Respiratory Health Research
- Streptococcal Infections and Treatments
- Pharmaceutical studies and practices
- Pediatric Urology and Nephrology Studies
- Neonatal and Maternal Infections
- Ureteral procedures and complications
- Blood disorders and treatments
- Lymphoma Diagnosis and Treatment
- Urological Disorders and Treatments
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Eosinophilic Disorders and Syndromes
- Hematological disorders and diagnostics
- Neuroblastoma Research and Treatments
- Parvovirus B19 Infection Studies
- Neonatal Health and Biochemistry
- Infective Endocarditis Diagnosis and Management
- Ethics and bioethics in healthcare
- Ethics in Clinical Research
Hospital Roberto del Rio
2011-2023
University of Chile
2004-2023
Hospital del Salvador
2018
Pediatric Oncology Group
2018
University Hospital Schleswig-Holstein
2013
University of Lübeck
2013
Centro Hospitalario Pereira Rossell
2013
Charles University
2013
University Hospital in Motol
2013
Infant
2007
From 2002 to 2007, the International Berlin-Frankfurt-Münster Study Group conducted a prospective randomized clinical trial (ALL IC-BFM 2002) for management of childhood acute lymphoblastic leukemia (ALL) in 15 countries on three continents. The aim this was explore impact differential delayed intensification (DI) outcome all risk groups.For trial, 5,060 eligible patients were divided into groups according age, WBC, early treatment response, and unfavorable genetic aberrations. DI as...
Trials of imatinib have provided evidence activity in adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (ALL), but the drug's role when given multidrug chemotherapy to children is unknown. This study assesses safety and efficacy oral association a Berlin-Frankfurt-Munster intensive regimen allogeneic stem-cell transplantation for paediatric patients ALL.
Infant acute lymphoblastic leukemia (ALL) is characterized by KMT2A (MLL) gene rearrangements and coexpression of myeloid markers. The Interfant-06 study, comprising 18 national international study groups, tested whether myeloid-style consolidation chemotherapy superior to lymphoid style, the role stem-cell transplantation (SCT), which factors had independent prognostic value.Three risk groups were defined: low (LR): germline; high (HR): KMT2A-rearranged older than 6 months with WBC count...
The International Berlin-Frankfurt-Münster (BFM) study group conducted a on pediatric acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD) was assessed using flow cytometry (FCM), and the impact of early intensification methotrexate (MTX) dose survival evaluated.We included 6,187 patients younger than 19 years. MRD by FCM refined risk definition previously used in ALL intercontinental-BFM 2002 basis age, WBC count, unfavorable genetic aberrations, treatment response measured...
Infant acute lymphoblastic leukemia (ALL) is characterized by a high incidence of KMT2A gene rearrangements and poor outcome. We evaluated the value minimal residual disease (MRD) in infants with KMT2A-rearranged ALL treated within Interfant-06 protocol, which compared lymphoid-style consolidation (protocol IB) versus myeloid-style (araC, daunorubicin, etoposide/mitoxantrone, araC, etoposide).MRD was measured 249 DNA-based polymerase chain reaction rearranged KMT2A, immunoglobulin, and/or...
Monitoring of minimal residual disease (MRD) by flow cytometry (FCM) is a powerful prognostic tool for predicting outcomes in acute lymphoblastic leukemia (ALL). To apply FCM-MRD large, collaborative trials, dedicated laboratory staff must be educated to concordantly high levels expertise and their performance quality should continuously monitored. We sought install unique comprehensive training control (QC) program involving large number reference laboratories within the international...
Abstract Background The objectives of this study were: (1) to analyze the relation serum methotrexate (MTX) concentration with creatinine clearance, (2) compare leucovorin rescue dose administered patients based on one calculated according MTX levels, and (3) determine MTX‐related toxicity. Procedure Thirty children high‐risk non‐B acute lymphoblastic leukemia (ALL) treated national protocol (PINDA 92) ALL BFM 90, were randomized receive consolidation four doses either 1 or 2 g/m as a 24‐hr...
Abstract Background Interfant‐99 was an international collaborative treatment protocol for infants with acute lymphoblastic leukemia (ALL). Procedure We collected data on 103 at the time of their first high‐dose methotrexate (HD MTX), 5 g/m 2 . Children <6 months age received two‐third calculated dose based body surface area (BSA), children 6–12 three‐fourth dose, and >12 full dose. Results The median steady‐state MTX concentration end 24‐hr infusion 57.8 µM (range 9.5–313). systemic...
Background The National Chilean Pediatric Oncology Group, PINDA, reports the first prospective, nonrandomized trial for acute lymphoblastic leukemia (ALL), using a modified version of Berlin-Frankfurt-Munster protocol (ALL BFM 86). aim this study was to classify immunophenotypes, decrease cranial irradiation, and assess whether would improve survival rate. Procedure From June, 1987, 1992, 444 unselected children were diagnosed with ALL. Of them, 425 evaluable. Therapy stratified by risk....
In Chile, survival estimates for pediatric patients with cancer are comparable to those in the United States and Western Europe. Approximately 80% of these treated at government-supported centers, an estimated 65% cured. We reasoned that cure rates could be further improved if transplantation hematopoietic stem cells were available chemotherapy-resistant malignancy.Physicians nurses selected trained international a unit was developed Luis Calvo Mackenna Hospital Santiago. Between October...
We report the different presentation features and clinical outcome between two identical infant twins with acute lymphoblastic leukaemia a shared clonal disease MLL gene rearrangement. One twin relapsed died, but other is in complete remission >4 years after diagnosis. These data, similar observations on infants leukaemia, suggest that despite common utero , post‐natally these leukaemias can evolve independently, at rates, twinned individuals, usually fatal associated t(4;11)...